Bisphenol AP is anti-estrogenic and may cause adverse effects at low doses relevant to human exposure.
Environ Pollut. 2018 Jul 24. Epub 2018 Jul 24. PMID: 30077407
A recent increase in the use of bisphenol A (BPA) alternatives to manufacture plastics has led to safety concerns. Here, we evaluated the estrogenic and anti-estrogenic activities of bisphenol AP (BPAP), a poorly studied BPA alternative, using in vitro, in vivo and in silico tools. BPAP exhibited weak estrogenicity but strong anti-estrogenicity (IC = 2.35 μM) in a GeneBLAzer™ β-lactamase reporter gene assay. BPAP, when administered alone or in combination with E(50 μg kgbw d) for 3 d, significantly decreased the uterine weights of post-weaning CD-1 mice at doses of 10 mg kgbw dand higher. When administered alone to prepubertal CD-1 mice for 10 d, BPAP significantly decreased the uterine weights at doses of 80 μg kgbw dand higher. Toxicogenomic analysis showed that BPAP regulated an opposite patterns of gene expression than that of Ein mouse uteri. In a glucose tolerance test using male mice, BPAP was found to disrupt the blood glucose homeostasis at low doses relevant to human exposure (1 and 100 μg kgbw d). Our results suggest that BPAP should be of great concern which might affect the sexual development in immature feminine and disrupt the blood glucose homeostasis at very low doses.